Magenta Therapeutics, Inc. Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100 million initial public offering of common stock of Magenta Therapeutics, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “MGTA.”

Headquartered in Cambridge, Massachusetts, Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics focused on critical areas of unmet need in the field of bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases.

The Davis Polk capital markets team included partner Deanna L. Kirkpatrick and associates Jennifer Ying Lan, Carrie Guo and Andrea Feuer. Counsel David R. Bauer and associate Jesse L. Hallock provided intellectual property and technology advice. Partner Michael Mollerus provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.